Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WM-A1-3389 Monotherapy and Combination with Pembrolizumab in Solid Tumors
NCT05872867Phase 1Recruiting
- Sponsor
- Wellmarker Bio
- Start
- Mar 2024
- Primary completion
- Feb 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of WM-A1-3389 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Wellmarker Bio. Primary endpoints: Incidence of Dose Limit Toxicities, Number of Participants Who Experienced an Adverse Event up to 18 weeks and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
WM-A1-3389
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05872867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872867.